Anoro Ellipta

Description

Anoro Ellipta
(Umeclidinium 62.5mcg / Vilanterol 25mcg)

Description:
Anoro Ellipta is a combination inhalation medication used for the long-term management of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It contains two active ingredients: umeclidinium (a long-acting muscarinic antagonist, or LAMA) and vilanterol (a long-acting beta-agonist, or LABA). Together, these medications help relax the muscles around the airways to prevent spasms and improve airflow in the lungs, making it easier to breathe.

Anoro Ellipta is prescribed as a once-daily inhaler for patients with COPD who need maintenance treatment to control symptoms such as wheezing, shortness of breath, and coughing. By combining a muscarinic antagonist with a beta-agonist, Anoro Ellipta provides a dual mechanism of action that helps reduce airway constriction and improve lung function for individuals suffering from chronic respiratory conditions.

Key Features:

• Dual-Action Formula: Combines umeclidinium, a LAMA, which works by blocking the effects of acetylcholine on airway smooth muscle, and vilanterol, a LABA, which stimulates beta receptors to relax airway muscles and improve airflow.
• Long-Lasting Effect: Provides 24-hour relief with a single dose, helping control symptoms throughout the day and night.
• Once-Daily Use: Convenient, easy-to-use inhaler that only requires one dose per day, improving patient compliance and convenience.
• FDA-Approved for COPD: Anoro Ellipta is specifically indicated for the long-term maintenance treatment of COPD and is not intended for relief of acute bronchospasm or sudden breathing problems.
• Designed for Optimal Delivery: The Ellipta inhaler is designed for simplicity and ease of use, delivering accurate doses of medication with every puff. It’s pre-loaded, so there’s no need for measuring or preparation.